Advance of treatment in hormone refractory prostate cancer

doi:10.3760/cma.j.issn.1673-422X.2014.01.018

Abstract

Abstract: Treatment with docetaxel and prednisone every 3 weeks is preferred in hormone refractory prostate cancer. In recent years, a number of clinical trials are held to assess the efficacy of docetaxelbased regimens combined with antiangiogenesis agents, firstline treatment of androgen ablation, and salvage therapy after chemotherapy failure with docetaxel. For hormone refractory prostate cancer, abiraterone can be used as the first choice, while, enzalutamide can be used as another endocrine therapy for patients who tolerate with docetaxel. However, chemotherapy combined with targeted drugs still cannot challenge the firstline treatment status of docetaxel plus prednisone.

Key words: Prostatic neoplasms, Drug therapy, Drug resistance, neoplasm, Androgen antagonists

Wang Ying, Li Xuyuan, Lin Yingcheng. Advance of treatment in hormone refractory prostate cancer[J]. Journal of International Oncology, 2014, 41(1): 56-59.

References

［1］ Seruga B, Tannock IF. Chemotherapybased treatment for castrationresistant prostate cancer［J］. J Clin Oncol, 2011, 29(27):36863694. ［2］ Kelly WK, Halabi S, Carducci M, et al. Randomized, doubleblind, placebocontrolled phase Ⅲ trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castrationresistant prostate cancer: CALGB 90401［J］. J Clin Oncol, 2012, 30(13):15341540. ［3］ Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castrationresistant prostate cancer (VENICE): a phase 3, doubleblind randomised trial［J］. Lancet Oncol, 2013, 14(8):760768. ［4］ Heidenreich A, Rawal SK, Szkarlat K, et al. A randomized, doubleblind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the firstline treatment of patients with metastatic castrationresistant prostate cancer［J］. Ann Oncol, 2013, 24(2):329336. ［5］ Sonpavde G, Matveev V, Burke JM, et al. Randomized phase Ⅱ trial of docetaxel plus prednisone in combination with placebo or AT101, an oral small molecule Bcl2 family antagonist, as firstline therapy for metastatic castrationresistant prostate cancer［J］. Ann Oncol, 2012, 23(7):18031808. ［6］ Chi KN, Hotte SJ, Yu EY, et al. Randomized phase Ⅱ study of docetaxel and prednisone with or without OGX011 in patients with metastatic castrationresistant prostate cancer［J］. J Clin Oncol, 2010, 28(27):42474254. ［7］ Scher HI, Jia X, Chi K, et al. Randomized, openlabel phase Ⅲ trial of docetaxel plus highdose calcitriol versus docetaxel plus prednisone for patients with castrationresistant prostate cancer［J］. J Clin Oncol, 2011, 29(16):21912198. ［8］ Fizazi KS, Higano CS, Nelson JB, et al. Phase Ⅲ, randomized, placebocontrolled study of docetaxel in combination with zibotentan in patients with metastatic castrationresistant prostate cancer［J］. J Clin Oncol, 2013, 31(14):17401747. ［9］ Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy［J］. N Engl J Med, 2013, 368(2):138148. ［10］ Kantoff PW, Higano CS, Shore ND, et al. SipuleucelT immunotherapy for castrationresistant prostate cancer［J］. N Engl J Med, 2010, 363(5):411422. ［11］ Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase Ⅱ randomized controlled trial of a Poxviralbased PSAtargeted immunotherapy in metastatic castrationresistant prostate cancer［J］. J Clin Oncol, 2010, 28(7):10991105. ［12］ Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castrationresistant prostate cancer: final overall survival analysis of the COUAA301 randomised, doubleblind, placebocontrolled phase 3 study［J］. Lancet Oncol, 2012, 13(10):983992. ［13］ Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy［J］. N Engl J Med, 2012, 367(13):11871197. ［14］ de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial［J］. Lancet, 2010, 376(9747):11471154. ［15］ Fleming MT, Sonpavde G, Kolodziej M, et al. Association of rash with outcomes in a randomized phase Ⅱ trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castrationresistant prostate cancer［J］. Clin Genitourin Cancer, 2012, 10(1):614. ［16］ Fizazi K, De Bono JS, Flechon A, et al. Randomised phase Ⅱ study of siltuximab (CNTO 328), an antiIL6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castrationresistant prostate cancer［J］. Eur J Cancer, 2012, 48(1):8593. ［17］ Ryan CJ, Rosenthal M, Ng S, et al. Targeted MET inhibition in castrationresistant prostate cancer: a randomized phase Ⅱ study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone［J］. Clin Cancer Res, 2013, 19(1):215224. ［18］ Nakabayashi M, Werner L, Courtney KD, et al. Phase Ⅱ trial of RAD001 and bicalutamide for castrationresistant prostate cancer［J］. BJU Int, 2012, 110(11):17291735. ［19］ Beardsley EK, Hotte SJ, North S, et al. A phase Ⅱ study of sorafenib in combination with bicalutamide in patients with chemotherapynaive castration resistant prostate cancer［J］. Invest New Drugs, 2012, 30(4):16521659. ［20］ Vogelzang NJ, Helle SI, Johannessen DC, et al. Efficacy and safety of radium233 dichloride (Ra233) in castrationresistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase Ⅲ ALSYMPCA trial［J］. J Clin Oncol, 2013, 31 Suppl 15:S5068.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[3]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[4]	Zhao Xin, Fan Xuewu, Tian Long, Hu Yimin. Application and evaluation study of 3D ultrasound in image guided radiotherapy for prostate cancer [J]. Journal of International Oncology, 2024, 51(1): 43-49.
[5]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[6]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[7]	Chen Yi, Han Liang, Cai Li. Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors [J]. Journal of International Oncology, 2022, 49(9): 521-525.
[8]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie. Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data [J]. Journal of International Oncology, 2022, 49(7): 408-415.
[9]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[10]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[11]	Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng. Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(11): 665-670.
[12]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50.
[13]	Long Xin, Wu Han, Peng Jin, Zhou Fuxiang. Systemic therapy of advanced biliary tract cancer [J]. Journal of International Oncology, 2021, 48(5): 302-307.
[14]	Du Xiao, Zhou Juying. Stereotactic body radiotherapy for localized prostate cancer [J]. Journal of International Oncology, 2021, 48(5): 313-316.
[15]	Song Yang, Wang Bin, Xiao He, Chen Chuan, Wang Ge, Geng Mingying. Predictive value of tumor regression rate after induction chemotherapy for survival of patients with locally advanced nasopharyngeal carcinoma [J]. Journal of International Oncology, 2021, 48(3): 156-163.